AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Trace gas analysis === Several techniques use ions created in a dedicated ion source injected into a flow tube or a drift tube: selected ion flow tube (SIFT-MS), and proton transfer reaction (PTR-MS), are variants of chemical ionization dedicated for trace gas analysis of air, breath or liquid headspace using well defined reaction time allowing calculations of analyte concentrations from the known reaction kinetics without the need for internal standard or calibration. Another technique with applications in trace gas analysis field is secondary electrospray ionization (SESI-MS), which is a variant of electrospray ionization. SESI consist of an electrospray plume of pure acidified solvent that interacts with neutral vapors. Vapor molecules get ionized at atmospheric pressure when charge is transferred from the ions formed in the electrospray to the molecules. One advantage of this approach is that it is compatible with most ESI-MS systems.
Muslims will then serve the favored four communities, while faithful Druze believers will be appointed as leaders. In his numerous epistles addressed to Christians, Bahā'-al-Dīn frequently refers to them as "saints" and "assemblies of saints". His writings also show a remarkable familiarity with the New Testament and Christian liturgy.
Aerobic exercise comprises innumerable forms. In general, it is performed at a moderate level of intensity over a relatively long period of time. For example, running a long distance at a moderate pace is an aerobic exercise, but sprinting is not. Playing singles tennis, with near-continuous motion, is generally considered aerobic activity, while activities with brief bursts of energetic movement within longer periods of casual movement may not be aerobic. Some sports are thus inherently "aerobic", while other aerobic exercises, such as fartlek training or aerobic dance classes, are designed specifically to improve aerobic capacity and fitness. It is most common for aerobic exercises to involve the leg muscles, primarily or exclusively. There are some exceptions. For example, rowing to distances of 2,000 meters or more is an aerobic sport that exercises several major muscle groups, including those of the legs, abdominals, chest, and arms.
There are also refrigeration systems that have two compressors for very precise and low-temperature operations, such as transporting a container of blood to a war zone. Cargoes of shrimp, asparagus, caviar and blood are considered among the most expensive refrigerated items. Bananas, fruit and meat have historically been the main cargo of refrigerated ships.
Sources: en.wikipedia.org
Researchers at the MD Anderson Cancer Center activated the telomerase reverse transcriptase gene, which declines with age, in mice and found that it both lengthened telomeres in cells and that signs of aging in cells that had not synthesized telomeres were also ameliorated suggesting that telomerase reverse transcriptase is responsible for regulating genes involved in aging independent of its role in building telomeres. Researchers at the Institute for Research in Biomedicine demonstrated that senescent cells release mt-dsRNA into the cytosol driving the SASP via RIGI/MDA5/MAVS/MFN1, and in turn are hypersensitive to mt-dsRNA-driven inflammation due to reduced levels of PNPT1/ADAR1. Moreover, senescent cells within fibrotic and aged tissues also present increased dsRNA foci, and inhibition of mitochondrial RNA polymerase reduces systemic inflammation associated to senescence. A study at Tufts Medical Center identified more than 300 unique metabolic markers associated with aging, extreme longevity, and mortality. Researchers at Stanford University reported reversing signs of Alzheimer's disease in the brains of mice by removing the enzyme IDO1, which changed the behavior of astrocytes, as IDO1 levels rise in the brain and astrocytes stop performing their function when Alzheimer's appears. The results were repeated with human astrocytes and neurons from Alzheimer's patients.
== Structure == The 3D structure of human serum albumin has been determined by X-ray crystallography to a resolution of 2.5 ångströms (250 pm). Albumin is a 65–70kDa protein. Albumin comprises three homologous domains that assemble to form a heart-shaped protein. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. Structurally, the serum albumins are similar, each domain containing five or six internal disulfide bonds.
Seeded 13th, he earned his first victory over Alexander Bublik by beating him in the first round in three sets. In the second round, he defeated world No. 29, Roberto Bautista Agut, in the second round. In the third round, he lost to third seed, Daniil Medvedev, despite serving for the match twice and having two match points in the third-set tie-break. This defeat was his seventh out of the last eight matches played with Medvedev. Seeded third at the BMW Open in Munich, he was defeated in the second round by Christopher O'Connell. Seeded 13th at the Madrid Open, he recorded his 350th career win by defeating Roberto Carballés Baena in the second round, becoming the only player under 30 to reach this milestone. In the third round, he overpowered qualifier, Hugo Grenier, in 55 minutes. In the fourth round, he lost to top seed, world No. 2, defending champion, and eventual champion, Carlos Alcaraz, in a rematch of the previous year's final. Failing to defend his finalist points from last year, his ranking fell from 16 to 22. Seeded 19th at the Italian Open, he made it to the fourth round where he lost to third seed and eventual champion, Daniil Medvedev. Having made the semifinals last year, his ranking again fell, this time from 22 to 27. Seeded third at the Geneva Open, he reached the semifinal where he lost to Nicolás Jarry, who would end up winning the tournament. Seeded 22nd at the French Open, he defeated Lloyd Harris, Alex Molčan, 12th seed Frances Tiafoe, and 28th seed Grigor Dimitrov in his first four rounds. In the quarterfinals, he faced Tomás Martín Etcheverry.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.